Fujian Provincial Cancer Hospital
Welcome,         Profile    Billing    Logout  
 124 Trials 
310 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ellard, Susan
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
CRI-CCTG-0003/IND.240, NCT04918186: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Recruiting
2
60
Canada, US
Durvalumab, BA3011, BA3021, ENB003, Toripalimab
Canadian Cancer Trials Group, Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.
Ovarian Cancer
06/25
12/25
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
PC-PEP, NCT04895839: Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Recruiting
N/A
500
Canada, RoW
Patient Empowerment Program
Nova Scotia Health Authority
Prostate Cancer
09/25
10/25
Ayoub, Jean-Pierre
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
06/25
12/26
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
Lu, Taixiang
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Recruiting
3
120
RoW
Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy
Sun Yat-sen University, Chinese Southwest Oncology Group
Nasopharyngeal Carcinoma
01/23
 
SUN, Xu Shan
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
4
334
RoW
Kanglaite Injection+Chemotherapy, Chemotherapy
Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
NSCLC
03/22
05/22
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
NCT06678230: Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Not yet recruiting
2
40
RoW
Anlotinib, Eribulin
The First Hospital of Jilin University
Breast Cancer
10/25
10/25
OMET, NCT03070366: Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

Active, not recruiting
2
78
Europe
Chemotherapy, Stereotactic radiotherapy
Groupe Oncologie Radiotherapie Tete et Cou
Head and Neck Squamous Cell Carcinoma
07/26
07/26
NCT06340165: A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Recruiting
N/A
153
RoW
Anlotinib
The First Hospital of Jilin University
Breast Cancer
06/25
06/25
Liu, Jian Xiong
ELEGANT, NCT06385093: A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Not yet recruiting
4
314
RoW
Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets
Chinese SLE Treatment And Research Group, Beijing Life oasis public service center
Rheumatoid Arthritis, Osteoporosis, Osteopenia
12/25
03/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting
2/3
374
RoW
SPH4336 Tablets 400mg, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
05/25
05/25
NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

Not yet recruiting
2
63
NA
Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate
Fujian Medical University
HER2-positive Recurrent/Metastatic Breast Cancer
12/24
12/25
NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting
1
98
RoW
Paclitaxel Micelles for Injection, Paclitaxel injection
First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD.
Advanced Solid Tumors
10/24
12/24
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting
1
156
RoW
HSK29116
Haisco Pharmaceutical Group Co., Ltd.
Relapsed/Refractory B-Cell Malignancies
08/23
10/23
NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Completed
1
24
RoW
Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA
Zai Lab (Hong Kong), Ltd.
Healthy Volunteer
09/24
09/24
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed
1
176
RoW
CMG901
Keymed Biosciences Co.Ltd
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
04/24
04/24
HF1K16-101, NCT05388487: Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Recruiting
1
54
RoW
HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg
HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd
Solid Tumor, Adult
04/25
11/25
NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Not yet recruiting
N/A
286
RoW
Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin
Fifth Affiliated Hospital, Sun Yat-Sen University
Pulmonary Tuberculosis
02/23
02/24
IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting
N/A
440
RoW
Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra
Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
04/23
09/24
MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Active, not recruiting
N/A
722
RoW
Onyx, Burr-hole, Medical Management
Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center
Subdural Hematoma, Non-acute
08/23
06/24
NCT04575207: The Flash FFR Ⅱ Study

Recruiting
N/A
2132
RoW
caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve
Peking University First Hospital, Rainmed Ltd., Suzhou, China
Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention
12/23
12/25
ZYYY-IIT-TNBC-001, NCT06371274: A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Not yet recruiting
N/A
32
RoW
ATRA, Toripalimab
First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance
Triple-negative Breast Cancer
04/26
04/26
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting
N/A
2000
RoW
Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation
Beijing 302 Hospital
HBV, Chronic Hepatitis b
12/28
12/28
NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction.

Recruiting
N/A
567
RoW
Possible risk factors of heart failure
Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital
Heart Failure, Acute Myocardial Infarction
12/25
12/25
Wang, Tao
EIVCIMFAELA, NCT06354582: Effect of Intravenous Vitamin C on Intrapartum Maternal Fever After Epidural Labor Analgesia

Recruiting
4
400
RoW
Vitamin C Injection, Suicheng, H20046552, Normal saline
Kunyue Li, Third Affiliated Hospital of Zhengzhou University
Obstetric Labor Complications, Fever
10/24
10/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT06049927: A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Completed
3
3300
RoW
Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV), Trivalent influenza vaccine(BY)
Sinovac Biotech Co., Ltd
Seasonal Influenza
05/24
05/24
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NCT05726110: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
3
50
RoW
Selinexor, KPT-330, Homoharringtonine, HHT, Daunorubicin, DNR, Cytarabine, Ara-C, Granulocyte Colony-Stimulating Factor, G-CSF, Aclacinomycin, ACM
Shanxi Bethune Hospital, Antengene Corporation
Relapsed or Refractory Acute Myeloid Leukemia
12/24
12/24
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT05402722: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Recruiting
2
30
RoW
Eribulin, Halaven, anti-PD-1 antibody
Beijing 302 Hospital
TNBC - Triple-Negative Breast Cancer
12/22
06/23
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Completed
2
240
RoW
3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
01/25
03/25
NCT06418594: Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Recruiting
2
30
RoW
Adebrelimab, Apatinib, Apatinib Mesylate Tablets, Etoposide, VP-16
Beijing 302 Hospital
HER2-negative Breast Cancer Brain Metastases
11/25
12/26
BicureX, NCT05978609: Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Recruiting
2
65
RoW
Candonilimab, Cisplatin, Gemcitabine
West China Hospital
Cholangiocarcinoma Non-resectable
07/25
07/26
RESCO, NCT06303414: Revascularization for Symptomatic Non-acute Carotid Artery Occlusion

Recruiting
N/A
1000
RoW
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS), Hybrid Surgery
Xuanwu Hospital, Beijing
Non-acute Carotid Artery Occlusion
12/28
12/28
NCT06135194: Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Recruiting
N/A
30
RoW
T-DXd, DS-8201
Beijing 302 Hospital
Breast Cancer
12/23
06/24
Precision1000, NCT04509271: Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease

Recruiting
N/A
1300
RoW
MicRNAs battery kits
Shanghai Mental Health Center
Alzheimer Disease
01/22
09/22
NCT04137926: A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease

Recruiting
N/A
360
RoW
MicRNAs battery
Shanghai Mental Health Center
Alzheimer's Disease
08/22
11/22
NCT03810794: Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease

Recruiting
N/A
180
RoW
Acupuncture, Donepezil, Donepezil Hydrochloride Tablets
Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center, Huashan Hospital
Alzheimer Disease, Cognitive Impairment
12/24
12/24
NCT03672448: The China Longitudinal Aging Study of Cognitive Impairment

Recruiting
N/A
10000
RoW
Naturalistic observation, Normal Aging
Shanghai Mental Health Center
Mild Cognitive Impairment, Alzheimer Disease, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Depression, Anxiety
11/23
11/23
NCT06155032: Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion

Recruiting
N/A
272
RoW
Endovascular therapy, EVT group, Best medical management, Best medical management group
First Affiliated Hospital of Wannan Medical College, The First Affiliated Hospital of Anhui Medical University
Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive
12/25
03/26
NCT05906719: Machine Vision Based MDS-UPDRS III Machine Rating

Recruiting
N/A
871
RoW
video recording
Ruijin Hospital, Second Affiliated Hospital of Soochow University, Beijing Hospital, Beijing Tiantan Hospital, Wuhan Union Hospital, China, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, West China Hospital
Parkinsonian Disorders, Machine Learning
04/24
04/24
NCT06412107: Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors

Recruiting
N/A
108
RoW
True acupressure, Sham acupressure, Usual care
Charles Darwin University, Second Affiliated Hospital of Zunyi Medical University, Zunyi Medical College
Breast Neoplasm Female, Symptom Cluster
02/25
06/25
NCT06650553: Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study

Recruiting
N/A
110
RoW
Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.
Shanxi Bethune Hospital
Aplastic Anemias
06/26
07/26
NCT05834699: HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
N/A
50
RoW
HER2 expression of circulating tumor cells
Beijing 302 Hospital
Breast Cancer
12/24
04/25
NCT05834686: HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
N/A
50
RoW
HER2 expression of circulating tumor cells
Beijing 302 Hospital
Breast Cancer
12/24
04/25
NCT05905874: Machine Learning-based Models in Prediction of DVT and PTE in AECOPD Patients

Recruiting
N/A
1000
RoW
Machine learning-based prediction model
West China Hospital, University of Chinese Academy of Sciences - Shenzhen Hospital, Affiliated Hospital of North Sichuan Medical College, Nanchong Central Hospital
Machine Learning, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease With Acute Exacerbation, Unspecified, Pulmonary Thromboembolisms, Deep Vein Thrombosis
12/24
12/24
NCT05870436: A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population

Recruiting
N/A
1100
RoW
Methacholine Choline Provocation Test
jingping Zheng, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
01/25
06/25
zypg001, NCT06728891: Analysis of Tumor Deposit At the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients with Gastric Cancer Who Received Proximal Gastrectomy

Not yet recruiting
N/A
100
RoW
In addition to routine diagnosis and treatment, no additional intervention measures were taken.
Jichao Qin
Gastric Carcinoma
12/27
12/27
zytg001, NCT06728878: Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer

Not yet recruiting
N/A
150
RoW
Jichao Qin
Gastric Cancers
12/27
12/27
CRICS, NCT05134246: Carotid Revascularization for Radiation Induced Carotid Artery Stenosis

Recruiting
N/A
150
RoW
Carotid endarterectomy (CEA), Carotid artery stenting (CAS)
Xuanwu Hospital, Beijing, Guangdong Provincial People's Hospital
Radiation-induced Carotid Artery Stenosis
12/26
12/27
NCT05276713: Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Recruiting
N/A
50
RoW
Tucidinostat, Chidamide
Beijing 302 Hospital
Breast Cancer
06/22
08/22
NCT05380999: The Red Blood Cells Based Blood Test for Lung Cancer EARLY Detection

Not yet recruiting
N/A
852
NA
Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Peking Union Medical College Hospital, Shanghai Chest Hospital, Guangzhou Panyu Central Hospital, My-BioMed Technology （Guangzhou） Co., Ltd.
Lung Cancer, Red Blood Cells, Methylation
03/25
03/26
Yang, Yu
NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Recruiting
4
38
RoW
Recombinant human growth hormone
GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University
Achondroplasia
02/25
02/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
NCT06927310: The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

Not yet recruiting
3
300
RoW
Inpegsomatropin Injection, Recombinant Human Growth Hormone Injection
Xiamen Amoytop Biotech Co., Ltd., Tongji Hospital
Idiopathic Short Stature
03/26
06/28
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Recruiting
3
93
US, RoW
Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd.
Puberty; Precocious, Central
11/25
06/26
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting
3
878
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
06/26
07/28
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

Recruiting
2a
60
RoW
50561 high dose, 50561 low dose, Placebo
Beijing Joekai Biotechnology LLC
Alzheimer's Disease
05/24
06/24
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Recruiting
2
80
RoW
TQ-B3525
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed / Refractory Follicular Lymphoma
12/22
12/22
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Completed
2
178
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
02/24
02/24
TQB2102-II-03, NCT06496490: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting
2
270
RoW
TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
10/25
02/26
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting
1
108
RoW
MRG001
Shanghai Miracogen Inc.
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
10/22
10/23
Chen, Ling
NCT05021094: Clinical Observation on Kuntai Capsule in Treating Early-onset Ovarian Hypofunction

Recruiting
4
120
RoW
Kuntai Capsule, Kuntai Jiaonang, Femoston, Complex Packing Estradiol Tablets/Estradiol and Dydrogesterone Tablets
Affiliated Hospital of Nantong University
Primary Ovarian Insufficiency
12/23
12/23
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.

Recruiting
3
1600
RoW
rhNRG-1, Neucardin™, Placebo
Zensun Sci. & Tech. Co., Ltd.
Chronic Heart Failure
02/26
02/26
NCT05451615: Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Recruiting
3
90
RoW
Janus Kinase Inhibitor, Abatacept
Zhejiang Provincial People's Hospital
Abatacept, Treatment Compliance, Rheumatoid Arthritis
06/23
06/24
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT05420324: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

Completed
2
20
RoW
YH003, Pembrolizumab, albumin paclitaxel
Eucure (Beijing) Biopharma Co., Ltd
Mucosal Melanoma
03/24
03/24
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Terminated
1/2
7
RoW
TJ1133 Injection
TJ Biopharma Co., Ltd.
Advanced Solid Tumor
02/23
02/23
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1/2
114
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
09/24
12/24
NCT05868083: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recruiting
1
16
RoW
SNC-109 CAR-T Cells
Shanghai Simnova Biotechnology Co.,Ltd., Chinese PLA General Hospital
Recurrent Glioblastoma Multiforme
05/24
08/24
NCT04783441: Use of CGM in Kidney Transplant Recipients

Recruiting
N/A
80
US
Dexcom G6, Dexcom G6 blinded sensor
University of California, Davis, DexCom, Inc.
Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
12/25
12/25
NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting
N/A
2000
RoW
Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation
Beijing 302 Hospital
HBV, Chronic Hepatitis b
12/28
12/28
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients

Recruiting
N/A
2000
RoW
Observational study, no intervention
Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University
Acute Stroke
10/22
10/23
Wu, hui R
DCAP, NCT04868565: Target Weaning Oxygen to Determine Cafffeine Duration for AOP

Completed
4
310
RoW
Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Children's Hospital of Chongqing Medical University
Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen
10/23
10/23
NCT06537115: Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia

Recruiting
4
450
RoW
exercise, whey protein powder, Eldecalcitol
Zhejiang Provincial People's Hospital
Sarcopenia
05/26
05/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT04253873: Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Recruiting
2
40
RoW
Apatinib, temozolomide
WuHui
High-grade Gliomas
12/21
12/22
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
170
RoW
abexinostat
Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma (DLBCL)
07/26
08/27
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting
2
64
RoW
LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection
Lyvgen Biopharma Holdings Limited
Head and Neck Squamous Cell Carcinoma
10/27
10/27
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT06845241: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Not yet recruiting
1/2
68
RoW
ICP-490
Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed or Refractory Non-Hodgkin Lymphoma
07/28
12/28
TQB2223-I-01, NCT05894421: TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Recruiting
1
92
RoW
TQB2223 injection+ Penpulimab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
01/25
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ellard, Susan
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
CRI-CCTG-0003/IND.240, NCT04918186: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Recruiting
2
60
Canada, US
Durvalumab, BA3011, BA3021, ENB003, Toripalimab
Canadian Cancer Trials Group, Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.
Ovarian Cancer
06/25
12/25
SKB264-II-06, NCT05642780: SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Recruiting
2
240
Europe, Canada, US, RoW
SKB264, Pembrolizumab, Keytruda
Klus Pharma Inc., Myriad Genetics, Inc., Discovery Life Sciences, LLC, Ventana Medical Systems, Inc, Frontage Laboratories, Inc.
Solid Tumor
11/26
12/27
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
PC-PEP, NCT04895839: Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Recruiting
N/A
500
Canada, RoW
Patient Empowerment Program
Nova Scotia Health Authority
Prostate Cancer
09/25
10/25
Ayoub, Jean-Pierre
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
06/25
12/26
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
Lu, Taixiang
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

Recruiting
3
120
RoW
Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy
Sun Yat-sen University, Chinese Southwest Oncology Group
Nasopharyngeal Carcinoma
01/23
 
SUN, Xu Shan
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
4
334
RoW
Kanglaite Injection+Chemotherapy, Chemotherapy
Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
NSCLC
03/22
05/22
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
NCT06678230: Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Not yet recruiting
2
40
RoW
Anlotinib, Eribulin
The First Hospital of Jilin University
Breast Cancer
10/25
10/25
OMET, NCT03070366: Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC

Active, not recruiting
2
78
Europe
Chemotherapy, Stereotactic radiotherapy
Groupe Oncologie Radiotherapie Tete et Cou
Head and Neck Squamous Cell Carcinoma
07/26
07/26
NCT06340165: A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Recruiting
N/A
153
RoW
Anlotinib
The First Hospital of Jilin University
Breast Cancer
06/25
06/25
Liu, Jian Xiong
ELEGANT, NCT06385093: A Study on the Prevention and Treatment of GIOP With Eldecalcitol

Not yet recruiting
4
314
RoW
Eldecalcitol capsules, Edirol, Alfacalcidol tablets, Calcium carbonate tablets
Chinese SLE Treatment And Research Group, Beijing Life oasis public service center
Rheumatoid Arthritis, Osteoporosis, Osteopenia
12/25
03/26
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting
3
405
Europe, Canada, US, RoW
Plozasiran Injection, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
07/26
10/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting
2/3
374
RoW
SPH4336 Tablets 400mg, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
05/25
05/25
NCT05621434: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer

Not yet recruiting
2
63
NA
Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate
Fujian Medical University
HER2-positive Recurrent/Metastatic Breast Cancer
12/24
12/25
NCT04778839: Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting
1
98
RoW
Paclitaxel Micelles for Injection, Paclitaxel injection
First Affiliated Hospital of Zhejiang University, Hangzhou Dihua Biotechnology Co., LTD.
Advanced Solid Tumors
10/24
12/24
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting
1
156
RoW
HSK29116
Haisco Pharmaceutical Group Co., Ltd.
Relapsed/Refractory B-Cell Malignancies
08/23
10/23
NCT06462326: A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Completed
1
24
RoW
Moxifloxacin Oral Tablet, Avelox, Omadacycline Oral Tablet, NUZYRA
Zai Lab (Hong Kong), Ltd.
Healthy Volunteer
09/24
09/24
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed
1
176
RoW
CMG901
Keymed Biosciences Co.Ltd
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
04/24
04/24
HF1K16-101, NCT05388487: Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

Recruiting
1
54
RoW
HF1K16 /Arm 45 mg/m², HF1K16 /Arm 90 mg/m², HF1K16 /Arm 120 mg/m², HF1K16 /Arm 160 mg/m², HF1K16 /Arm 120 mg or 180 mg
HighField Biopharmaceuticals Corporation, Tigermed Consulting Co., Ltd
Solid Tumor, Adult
04/25
11/25
NCT04187469: Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB

Not yet recruiting
N/A
286
RoW
Moxifloxacin, Isoniazid, Rifampicin, Avelox, Myambutol, Nydrazid, Rifampin, Rifadin, Rifampicin,Isoniazid,Pyrazinamide,Ethambutol, Myambutol,Nydrazid,Rifampin,Rifadin
Fifth Affiliated Hospital, Sun Yat-Sen University
Pulmonary Tuberculosis
02/23
02/24
IBBR, NCT03589924: Study to Compare the Safety of Immediate One-stage With Expander-Implant Two-stage Augmented With TiLoop® Bra(COSTA)

Active, not recruiting
N/A
440
RoW
Immediate IBBR+TiLoop®Bra, Immediate-delayed IBBR+TiLoop®Bra
Jiong Wu, First Hospital of China Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
04/23
09/24
MAGIC-MT, NCT04700345: Managing Non-acute Subdural Hematoma Using Liquid Materials：a Chinese Randomized Trial of MMA Treatment

Active, not recruiting
N/A
722
RoW
Onyx, Burr-hole, Medical Management
Huashan Hospital, Shanghai Municipal Health Commission, Shanghai Shen Kang Hospital Development Center
Subdural Hematoma, Non-acute
08/23
06/24
NCT04575207: The Flash FFR Ⅱ Study

Recruiting
N/A
2132
RoW
caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve
Peking University First Hospital, Rainmed Ltd., Suzhou, China
Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention
12/23
12/25
ZYYY-IIT-TNBC-001, NCT06371274: A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Not yet recruiting
N/A
32
RoW
ATRA, Toripalimab
First Affiliated Hospital of Zhejiang University, Shanghai Longfine Biotechnology Co., Ltd., TopAlliance
Triple-negative Breast Cancer
04/26
04/26
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting
N/A
2000
RoW
Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation
Beijing 302 Hospital
HBV, Chronic Hepatitis b
12/28
12/28
NCT05760157: Mulltimodal Dynamic Risk Assessment Systems of Heart Failure in Patients With Myocardial Infarction.

Recruiting
N/A
567
RoW
Possible risk factors of heart failure
Jian Liu, Peking University Third Hospital, Beijing Anzhen Hospital, Navy General Hospital, Beijing, Beijing Luhe Hospital, Beijing Chao Yang Hospital
Heart Failure, Acute Myocardial Infarction
12/25
12/25
Wang, Tao
EIVCIMFAELA, NCT06354582: Effect of Intravenous Vitamin C on Intrapartum Maternal Fever After Epidural Labor Analgesia

Recruiting
4
400
RoW
Vitamin C Injection, Suicheng, H20046552, Normal saline
Kunyue Li, Third Affiliated Hospital of Zhengzhou University
Obstetric Labor Complications, Fever
10/24
10/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT06049927: A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Completed
3
3300
RoW
Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml), Trivalent influenza vaccine(BV), Trivalent influenza vaccine(BY)
Sinovac Biotech Co., Ltd
Seasonal Influenza
05/24
05/24
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NCT05726110: Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
3
50
RoW
Selinexor, KPT-330, Homoharringtonine, HHT, Daunorubicin, DNR, Cytarabine, Ara-C, Granulocyte Colony-Stimulating Factor, G-CSF, Aclacinomycin, ACM
Shanxi Bethune Hospital, Antengene Corporation
Relapsed or Refractory Acute Myeloid Leukemia
12/24
12/24
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT05402722: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Recruiting
2
30
RoW
Eribulin, Halaven, anti-PD-1 antibody
Beijing 302 Hospital
TNBC - Triple-Negative Breast Cancer
12/22
06/23
TQC3721-II-03, NCT06527144: A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Completed
2
240
RoW
3mg TQC3721 Suspension for Inhalation, 6mg TQC3721 Suspension for Inhalation, Placebo TQC3721 suspension for inhalation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
01/25
03/25
NCT06418594: Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Recruiting
2
30
RoW
Adebrelimab, Apatinib, Apatinib Mesylate Tablets, Etoposide, VP-16
Beijing 302 Hospital
HER2-negative Breast Cancer Brain Metastases
11/25
12/26
BicureX, NCT05978609: Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer

Recruiting
2
65
RoW
Candonilimab, Cisplatin, Gemcitabine
West China Hospital
Cholangiocarcinoma Non-resectable
07/25
07/26
RESCO, NCT06303414: Revascularization for Symptomatic Non-acute Carotid Artery Occlusion

Recruiting
N/A
1000
RoW
Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS), Hybrid Surgery
Xuanwu Hospital, Beijing
Non-acute Carotid Artery Occlusion
12/28
12/28
NCT06135194: Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Recruiting
N/A
30
RoW
T-DXd, DS-8201
Beijing 302 Hospital
Breast Cancer
12/23
06/24
Precision1000, NCT04509271: Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease

Recruiting
N/A
1300
RoW
MicRNAs battery kits
Shanghai Mental Health Center
Alzheimer Disease
01/22
09/22
NCT04137926: A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease

Recruiting
N/A
360
RoW
MicRNAs battery
Shanghai Mental Health Center
Alzheimer's Disease
08/22
11/22
NCT03810794: Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease

Recruiting
N/A
180
RoW
Acupuncture, Donepezil, Donepezil Hydrochloride Tablets
Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center, Huashan Hospital
Alzheimer Disease, Cognitive Impairment
12/24
12/24
NCT03672448: The China Longitudinal Aging Study of Cognitive Impairment

Recruiting
N/A
10000
RoW
Naturalistic observation, Normal Aging
Shanghai Mental Health Center
Mild Cognitive Impairment, Alzheimer Disease, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Depression, Anxiety
11/23
11/23
NCT06155032: Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion

Recruiting
N/A
272
RoW
Endovascular therapy, EVT group, Best medical management, Best medical management group
First Affiliated Hospital of Wannan Medical College, The First Affiliated Hospital of Anhui Medical University
Stroke, Ischemic, Cerebrovascular; Disorder, Occlusive
12/25
03/26
NCT05906719: Machine Vision Based MDS-UPDRS III Machine Rating

Recruiting
N/A
871
RoW
video recording
Ruijin Hospital, Second Affiliated Hospital of Soochow University, Beijing Hospital, Beijing Tiantan Hospital, Wuhan Union Hospital, China, Fujian Medical University Union Hospital, Guangdong Provincial People's Hospital, West China Hospital
Parkinsonian Disorders, Machine Learning
04/24
04/24
NCT06412107: Somatic Acupressure for Symptom Cluster Management in Breast Cancer Survivors

Recruiting
N/A
108
RoW
True acupressure, Sham acupressure, Usual care
Charles Darwin University, Second Affiliated Hospital of Zunyi Medical University, Zunyi Medical College
Breast Neoplasm Female, Symptom Cluster
02/25
06/25
NCT06650553: Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study

Recruiting
N/A
110
RoW
Clinically diagnosed AA patients are divided into HLA-matched HSCT group and umbilical cord blood-supported haplo-HSCT group.
Shanxi Bethune Hospital
Aplastic Anemias
06/26
07/26
NCT05834699: HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
N/A
50
RoW
HER2 expression of circulating tumor cells
Beijing 302 Hospital
Breast Cancer
12/24
04/25
NCT05834686: HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
N/A
50
RoW
HER2 expression of circulating tumor cells
Beijing 302 Hospital
Breast Cancer
12/24
04/25
NCT05905874: Machine Learning-based Models in Prediction of DVT and PTE in AECOPD Patients

Recruiting
N/A
1000
RoW
Machine learning-based prediction model
West China Hospital, University of Chinese Academy of Sciences - Shenzhen Hospital, Affiliated Hospital of North Sichuan Medical College, Nanchong Central Hospital
Machine Learning, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease With Acute Exacerbation, Unspecified, Pulmonary Thromboembolisms, Deep Vein Thrombosis
12/24
12/24
NCT05870436: A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population

Recruiting
N/A
1100
RoW
Methacholine Choline Provocation Test
jingping Zheng, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
01/25
06/25
zypg001, NCT06728891: Analysis of Tumor Deposit At the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients with Gastric Cancer Who Received Proximal Gastrectomy

Not yet recruiting
N/A
100
RoW
In addition to routine diagnosis and treatment, no additional intervention measures were taken.
Jichao Qin
Gastric Carcinoma
12/27
12/27
zytg001, NCT06728878: Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer

Not yet recruiting
N/A
150
RoW
Jichao Qin
Gastric Cancers
12/27
12/27
CRICS, NCT05134246: Carotid Revascularization for Radiation Induced Carotid Artery Stenosis

Recruiting
N/A
150
RoW
Carotid endarterectomy (CEA), Carotid artery stenting (CAS)
Xuanwu Hospital, Beijing, Guangdong Provincial People's Hospital
Radiation-induced Carotid Artery Stenosis
12/26
12/27
NCT05276713: Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Recruiting
N/A
50
RoW
Tucidinostat, Chidamide
Beijing 302 Hospital
Breast Cancer
06/22
08/22
NCT05380999: The Red Blood Cells Based Blood Test for Lung Cancer EARLY Detection

Not yet recruiting
N/A
852
NA
Methylation tests of nucleic acids extracted from mature red blood cells (RBCs)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Peking Union Medical College Hospital, Shanghai Chest Hospital, Guangzhou Panyu Central Hospital, My-BioMed Technology （Guangzhou） Co., Ltd.
Lung Cancer, Red Blood Cells, Methylation
03/25
03/26
Yang, Yu
NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Recruiting
4
38
RoW
Recombinant human growth hormone
GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University
Achondroplasia
02/25
02/25
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
NCT06927310: The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

Not yet recruiting
3
300
RoW
Inpegsomatropin Injection, Recombinant Human Growth Hormone Injection
Xiamen Amoytop Biotech Co., Ltd., Tongji Hospital
Idiopathic Short Stature
03/26
06/28
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty

Recruiting
3
93
US, RoW
Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd.
Puberty; Precocious, Central
11/25
06/26
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting
3
878
RoW
JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy
Shanghai Junshi Bioscience Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
06/26
07/28
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

Recruiting
2a
60
RoW
50561 high dose, 50561 low dose, Placebo
Beijing Joekai Biotechnology LLC
Alzheimer's Disease
05/24
06/24
NCT04324879: A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)

Recruiting
2
80
RoW
TQ-B3525
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed / Refractory Follicular Lymphoma
12/22
12/22
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Completed
2
178
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
02/24
02/24
TQB2102-II-03, NCT06496490: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting
2
270
RoW
TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
10/25
02/26
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Recruiting
1
108
RoW
MRG001
Shanghai Miracogen Inc.
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
10/22
10/23
Chen, Ling
NCT05021094: Clinical Observation on Kuntai Capsule in Treating Early-onset Ovarian Hypofunction

Recruiting
4
120
RoW
Kuntai Capsule, Kuntai Jiaonang, Femoston, Complex Packing Estradiol Tablets/Estradiol and Dydrogesterone Tablets
Affiliated Hospital of Nantong University
Primary Ovarian Insufficiency
12/23
12/23
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.

Recruiting
3
1600
RoW
rhNRG-1, Neucardin™, Placebo
Zensun Sci. & Tech. Co., Ltd.
Chronic Heart Failure
02/26
02/26
NCT05451615: Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Recruiting
3
90
RoW
Janus Kinase Inhibitor, Abatacept
Zhejiang Provincial People's Hospital
Abatacept, Treatment Compliance, Rheumatoid Arthritis
06/23
06/24
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Active, not recruiting
3
186
RoW
Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB
Beijing Chest Hospital, National Medical Center for Infectious Diseases
Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
10/26
12/26
NCT05420324: A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

Completed
2
20
RoW
YH003, Pembrolizumab, albumin paclitaxel
Eucure (Beijing) Biopharma Co., Ltd
Mucosal Melanoma
03/24
03/24
NCT05148533: A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Terminated
1/2
7
RoW
TJ1133 Injection
TJ Biopharma Co., Ltd.
Advanced Solid Tumor
02/23
02/23
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1/2
114
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
09/24
12/24
NCT05868083: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recruiting
1
16
RoW
SNC-109 CAR-T Cells
Shanghai Simnova Biotechnology Co.,Ltd., Chinese PLA General Hospital
Recurrent Glioblastoma Multiforme
05/24
08/24
NCT04783441: Use of CGM in Kidney Transplant Recipients

Recruiting
N/A
80
US
Dexcom G6, Dexcom G6 blinded sensor
University of California, Davis, DexCom, Inc.
Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
12/25
12/25
NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting
N/A
2000
RoW
Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation
Beijing 302 Hospital
HBV, Chronic Hepatitis b
12/28
12/28
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients

Recruiting
N/A
2000
RoW
Observational study, no intervention
Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University
Acute Stroke
10/22
10/23
Wu, hui R
DCAP, NCT04868565: Target Weaning Oxygen to Determine Cafffeine Duration for AOP

Completed
4
310
RoW
Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Children's Hospital of Chongqing Medical University
Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen
10/23
10/23
NCT06537115: Clinical Intervention of Idecalcitol Combined With Whey Protein Powder and Exercise for Sarcopenia

Recruiting
4
450
RoW
exercise, whey protein powder, Eldecalcitol
Zhejiang Provincial People's Hospital
Sarcopenia
05/26
05/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT04253873: Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Recruiting
2
40
RoW
Apatinib, temozolomide
WuHui
High-grade Gliomas
12/21
12/22
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
170
RoW
abexinostat
Xynomic Pharmaceuticals, Inc.
Diffuse Large B-cell Lymphoma (DLBCL)
07/26
08/27
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting
2
64
RoW
LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection
Lyvgen Biopharma Holdings Limited
Head and Neck Squamous Cell Carcinoma
10/27
10/27
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
NCT06845241: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Not yet recruiting
1/2
68
RoW
ICP-490
Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed or Refractory Non-Hodgkin Lymphoma
07/28
12/28
TQB2223-I-01, NCT05894421: TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Recruiting
1
92
RoW
TQB2223 injection+ Penpulimab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
01/25
01/26
 

Download Options